Abstract
The protein degradation start-up Epi- Biologics has launched with $50 million in series A funding. It is targeting cell-surface and extracellular proteins using antibody-based PROTACs, a platform the company calls EpiTAC. EpiBiologics says its atlas of degraders will lead to new treatments for cancer, as well as for immunology and neuro-related conditions. EpiBiologics is based on the work of cofounder Jim Wells, an antibody engineer at the University of California, San Francisco.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
